MX2018004829A - Métodos para medir la actividad de factor d y la potencia de inhibidores de factor d. - Google Patents

Métodos para medir la actividad de factor d y la potencia de inhibidores de factor d.

Info

Publication number
MX2018004829A
MX2018004829A MX2018004829A MX2018004829A MX2018004829A MX 2018004829 A MX2018004829 A MX 2018004829A MX 2018004829 A MX2018004829 A MX 2018004829A MX 2018004829 A MX2018004829 A MX 2018004829A MX 2018004829 A MX2018004829 A MX 2018004829A
Authority
MX
Mexico
Prior art keywords
factor
methods
inhibitors
potency
activity
Prior art date
Application number
MX2018004829A
Other languages
English (en)
Inventor
Jia Xiaoqing
Orren Linda
Yee Wong Pin
Miller Aaron
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2018004829A publication Critical patent/MX2018004829A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21046—Complement factor D (3.4.21.46)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención de refiere a métodos para medir la actividad de Factor D, el activador clave en la activación de la ruta alternativa de complemento, métodos para determinar la potencia de inhibidores de Factor D, y a métodos para examinar inhibidores de Factor D.
MX2018004829A 2015-10-30 2016-10-27 Métodos para medir la actividad de factor d y la potencia de inhibidores de factor d. MX2018004829A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249073P 2015-10-30 2015-10-30
US201562250885P 2015-11-04 2015-11-04
PCT/US2016/059045 WO2017075170A1 (en) 2015-10-30 2016-10-27 Methods of measuring factor d activity and potency of factor d inhibitors

Publications (1)

Publication Number Publication Date
MX2018004829A true MX2018004829A (es) 2018-12-10

Family

ID=57396803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004829A MX2018004829A (es) 2015-10-30 2016-10-27 Métodos para medir la actividad de factor d y la potencia de inhibidores de factor d.

Country Status (14)

Country Link
US (1) US10591481B2 (es)
EP (2) EP3368682B1 (es)
JP (1) JP6911026B2 (es)
KR (1) KR20180066242A (es)
CN (1) CN108513585A (es)
AU (1) AU2016344146A1 (es)
BR (1) BR112018008673A2 (es)
CA (1) CA3002671A1 (es)
ES (1) ES2772696T3 (es)
HK (1) HK1257425A1 (es)
IL (1) IL258858A (es)
MX (1) MX2018004829A (es)
PL (1) PL3368682T3 (es)
WO (1) WO2017075170A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
WO2019190877A1 (en) * 2018-03-26 2019-10-03 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement c3 convertase
EP3902824A4 (en) * 2018-12-28 2023-01-04 Sparx Therapeutics Inc. FOR CLAUDIN 18.2 SPECIFIC BINDING MOLECULES, COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND OTHER DISEASES
CN114920842B (zh) * 2022-05-09 2023-07-04 华兰基因工程(河南)有限公司 特异性结合pv-1蛋白的抗体或其抗原结合片段及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
ES2488819T3 (es) 1998-02-20 2014-08-29 Genentech, Inc. Inhibidores de la activación del complemento
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
DE602006005806D1 (de) * 2006-07-28 2009-04-30 Vista Ventures Gmbh Verfahren zum Nachweis der amyloid-beta Oligomere in Körperflüssigkeiten
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
EA201000836A1 (ru) * 2007-11-21 2010-12-30 Эразмус Юниверсити Медикал Сентер Роттердам Улучшенные зонды для fret и их применение
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CN107337734A (zh) 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2011091086A1 (en) * 2010-01-19 2011-07-28 Sirigen Inc. Novel reagents for directed biomarker signal amplification
SG194780A1 (en) * 2011-05-05 2013-12-30 Wellstat Immunotherapeutics Llc Complement factor b analogs and their uses
JP6244350B2 (ja) * 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
US9056874B2 (en) * 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
EP2674167A1 (en) * 2012-06-14 2013-12-18 PLS-Design GmbH Controlled activation of complement components for use as endogenous adjuvant
WO2014028861A1 (en) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
AU2013326932B2 (en) * 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
JP6702866B2 (ja) * 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
US20180074077A1 (en) 2015-03-25 2018-03-15 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway

Also Published As

Publication number Publication date
WO2017075170A1 (en) 2017-05-04
IL258858A (en) 2018-06-28
CN108513585A (zh) 2018-09-07
EP3666901A1 (en) 2020-06-17
US20170122944A1 (en) 2017-05-04
BR112018008673A2 (pt) 2018-11-27
ES2772696T3 (es) 2020-07-08
AU2016344146A1 (en) 2018-05-10
WO2017075170A8 (en) 2017-08-03
PL3368682T3 (pl) 2020-05-18
US10591481B2 (en) 2020-03-17
HK1257425A1 (zh) 2019-10-18
EP3368682B1 (en) 2019-12-11
CA3002671A1 (en) 2017-05-04
JP2018537081A (ja) 2018-12-20
EP3368682A1 (en) 2018-09-05
KR20180066242A (ko) 2018-06-18
JP6911026B2 (ja) 2021-07-28

Similar Documents

Publication Publication Date Title
ZA202310395B (en) Substituted inhibitors of menin-mll and methods of use
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2023013342A (es) Celulas que expresan el receptor de antigeno quimerico (car) con funcion o expresion de tet reducida y metodos de uso de las mismas.
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501763A1 (en) Multispecific antibodies
TR201909887T4 (tr) ERK inhibitörleri olarak tieno[2,3-c]pirol-4-on türevleri.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2017006094A (es) Anticuerpos anti-interleucina-33 y sus usos.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2016000997A (es) Metodos y composiciones para detectar contaminacion bacteriana.
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
TN2017000435A1 (en) [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
MX2018004829A (es) Métodos para medir la actividad de factor d y la potencia de inhibidores de factor d.
AU2016361427A8 (en) Platinum anticancer agents
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.